Aerodynamically light particles for pulmonary drug delivery
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/00
A61K-009/14
A61K-049/00
A61L-015/00
출원번호
US-0441948
(2003-05-20)
발명자
/ 주소
Edwards, David A.
Caponetti, Giovanni
Hrkach, Jeffrey S.
Lotan, Noah
Hanes, Justin
Ben-Jebria, Abdellaziz
Langer, Robert S.
출원인 / 주소
Massachusetts Institute of Technology
The Penn State Research Foundation
대리인 / 주소
Elmore Craig, P.C.
인용정보
피인용 횟수 :
12인용 특허 :
73
초록▼
Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of biodegradable material and have a tap density of less than 0.4 g/cm3 and a m
Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of biodegradable material and have a tap density of less than 0.4 g/cm3 and a mass mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear α-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 μm, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The aerodynamically light particles incorporating a therapeutic agent may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide variety of therapeutic agents.
대표청구항▼
1. A mass of biocompatible particles comprising particles having a nucleic acid and wherein the particles have a mass mean diameter of 5 to 30 μm, a mass mean aerodynamic diameter of less than 4 μm and a tap density of less than about 0.4 g/cm3.2. The particles of claim 1, wherein the nucleic acid h
1. A mass of biocompatible particles comprising particles having a nucleic acid and wherein the particles have a mass mean diameter of 5 to 30 μm, a mass mean aerodynamic diameter of less than 4 μm and a tap density of less than about 0.4 g/cm3.2. The particles of claim 1, wherein the nucleic acid has therapeutic, prophylactic or diagnostic activities.3. The particles of claim 1, wherein the particles have a mass mean diameter from 5 μm to 15 μm.4. The particles of claim 1, wherein the particles have a mass mean diameterfrom 5 μm to 7 μm.5. The particles of claim 1, wherein the at least 90% of the particles have a mass mean diameter from 5 μm to about 30 μm.6. The particles of claim 1, wherein the particles have an aerodynamic diameter of less than 3 μm.7. The particles of claim 1, wherein the nucleic acid is selected from the group consisting of a gene, antisense molecule and ribozyme.8. The particles of claim 1, wherein the particles further comprise a biodegradable material.9. The particles of claim 8, wherein the biodegradable material is a polymeric material.10. The particles of claim 9, wherein the biodegradable material is a non-polymeric material.11. The particles of claim 1, wherein the particles have a tap density of less than about 0.1 g/cm3.12. A method for delivery of particles having an agent to the pulmonary system comprising,administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of biocompatible particles comprising therapeutic, prophylactic or diagnostic nucleic acid, and wherein the particles have a mass mean diameter of 5 to 30 μm, a mass mean aerodynamic diameter of less than 4 μm and a tap density of less than about 0.4 g/cm3. 13. The method of claim 12, wherein the diameter is a mass mean diameter from 5 μm to 15 μm.14. The method of claim 13, wherein the diameter is a mass mean diameter from 5 μm to 7 μm.15. The method of claim 12, wherein at least 90% of the particles have a mass mean diameter between 5 μm and 30 μm.16. The method of claim 12, wherein the particles have a mass mean aerodynamic diameter of less than 3 μm.17. The method of claim 12, wherein the nucleic acid is selected from the group consisting of a gene, antisense molecule and a ribozyme.18. The method of claim 12, wherein the particles further comprise a biodegradable material.19. The method of claim 18, wherein the biodegradable material is a polymeric material.20. The method of claim 19, wherein the biodegradable material is a non-polymeric material.21. The method of claim 12, wherein the particles have a tap density of less than about 0.1 g/cm3.22. The method of claim 12, wherein the agent is delivered to the deep lung.23. The method of claim 12, wherein the agent is delivered to the central airways.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (73)
David A. Edwards ; Giovanni Caponetti ; Jeffrey S. Hrkach ; Noah Lotan IL; Justin Hanes ; Abdellaziz Ben-Jebria ; Robert S. Langer, Aerodynamically light particles for pulmonary drug delivery.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Williams David R. (San Diego CA) Mecikalski Mark B. (Tucson AZ) Thueson David O. (Poway CA), Apparatus for aerosolizing powdered medicine and process and using.
Hilmann Juergen (Berlin DEX) Hoffmann Rolf-Ruediger (Berlin DEX) Muetzel Wolfgang (Berlin DEX) Zimmermann Ingfried (Berlin DEX), Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium.
Potter Dennis L. (Kernersville NC) Raker Mark L. (Clemmons NC) Ridings Henry T. (Lewisville NC) Sensabaugh ; Jr. Andrew J. (Winston-Salem NC) Westmoreland Amos E. (Winston-Salem NC) Woods Donna K. (W, Drug delivery article.
Illum Lisbeth (Nottingham GBX), Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving mater.
Torobin Leonard B. (Materials Technology Corporation ; Tower Place/Suite 1425 ; 3340 Peachtree Rd. ; NE. Atlanta GA 30026), Hollow porous microspheres containing biocatalyst.
Wise Donald L. (Belmont MA) Trantolo Debra J. (Princeton MA) Gresser Joseph D. (Brookline MA), Method for making a bioerodible material for the sustained release of a medicament and the material made from the method.
Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Eldridge John H. (Birmingham AL) Staas Jay K. (Birmingham AL) Hollingshead Melinda G. (Birmingham AL) Shannon William M. (Birmingham A, Method of potentiating an immune response.
Hommel Martin (Toronto CAX) Mein-Fang Sun Anthony (Willowdale CAX) Goosen Mattheus F. A. (Toronto CAX), Microcapsule composition suitable for cardiovascular injection.
Vassiliades Anthony E. (Deerfield IL) Shroff Shrenik (Lake Forest IL) Nauman Edward F. (Chicago IL), Oil-in-water emulsions containing hydropholeic starch.
Boyes Robert N. (St. Albans AL GB2) Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Pledger Kenneth L. (Huntsville AL), Pharmaceutical formulations comprising microcapsules.
Muranishi Shozo (Kyoto JPX) Ikada Yoshito (Kyoto JPX) Yoshikawa Hiroshi (Kyoto JPX) Gen Shokyu (Kyoto JPX), Polylactic acid microspheres and process for producing the same.
Hyon Suong-Hyu (Uji JPX) Ikada Yoshita (Uji JPX), Polylactic acid type microspheres containing physiologically active substance and process for preparing the same.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
David A. Edwards ; Giovanni Caponetti ; Jeffrey S. Hrkach ; Noah Lotan IL; Justin Hanes ; Robert S. Langer ; Abdellaziz Ben-Jebria, Porous particles comprising excipients for deep lung delivery.
Edwards David A. ; Caponetti Giovanni ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Langer Robert S. ; Ben-Jebria Abdellaziz, Porous particles for deep lung delivery.
Sutton Andrew D. (Ruddington GB2) Johnson Richard A. (West Bridgford GB2) Senior Peter J. (Near Melbourne GB2) Heath David (The Park GB2), Preparation of diagnostic agents.
Ek Bo R. (Stockholm SEX) Eriksson Kjell G. (Spnga SEX) Nyqvist Per Gustaf H. (Tullinge SEX) Ragnarsson Gert A. (Bro SEX), Process for the manufacture of porous cellulose matrices.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Leong Helen (Atherton CA) Katz Martin (Menlo Park CA) Delk Ann (Kensington CA) Nacht Sergio (Los Altos CA) Berliner David (Atherton CA), Synthetic melanin aggregates.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Systemic administration of a therapeutic preparation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Yakovlevsky, Kirill; Shamashkin, Michael; Khalaf, Nazer; Govardhan, Chandrika P.; Jung, Chu W., Spherical protein particles and methods for making and using them.
Dobry, Daniel E.; Mullin, James M.; Millard, Douglas L.; Friesen, Dwayne T.; Newbold, David D.; Baumann, John M.; Dubose, Devon B., Spray-drying apparatus and methods of using the same.
Dobry, Daniel E.; Mullin, James M.; Millard, Douglas L.; Friesen, Dwayne T.; Newbold, David D.; Baumann, John M.; Dubose, Devon B., Spray-drying apparatus and methods of using the same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.